TG Therapeutics Inc. Watch

from 8-K 47 pages TG Therapeutics, Inc. 6,320,000 Shares of Common Stock Underwriting Agreement

from 8-K 51 pages TG Therapeutics, Inc. 8,500,000 Shares of Common Stock Underwriting Agreement

from 8-K 37 pages TG Therapeutics, Inc. Common Stock (Par Value $0.001 Per Share) at Market Issuance Sales Agreement

from 8-K 45 pages Underwriting Agreement Between TG Therapeutics, Inc. and Jefferies LLC as Representative of the Several Underwriters TG Therapeutics, Inc. Underwriting Agreement

from 8-A12B 33 pages Stockholder Protection Rights Agreement Dated as of July 18, 2014 Between TG Therapeutics, Inc. and American Stock Transfer & Trust Company, LLC as Rights Agent Stockholder Protection Rights Agreement

from 8-K 2 pages We Are Acting as Counsel to TG Therapeutics, Inc., a Delaware Corporation (The “Company”) in Connection With the Registration Statement on Form S-3 (File No. 333-189015) Filed by the Company With the Securities and Exchange Commission (The “Commission”) Pursuant to the Securities Act of 1933, as Amended (The “Securities Act”), on May 31, 2013 (The “Registration Statement”) and Declared Effective by the Commission on June 17, 2013, and the Issuance and Sale of an Aggregate of 5,700,000 Shares (The “Shares”) of Common Stock, Par Value $0.001 Per Share, of the Company (The “Common Stock”) Off of the Registration Statement. the Company Is Selling the Shares to Roth Capital Partners, LLC, Ladenburg Thalmann & Co. Inc., Brean Capital, LLC and National Securities Corporation (The “Underwriters”) Pursuant to the Underwriting Agreement Dated July 18, 2013 (The “Underwriting Agreement”) Between the Company and the Underwriters. This Opinion Is Furnished to You at Your Request in Accordance With the Requirements of Item 16 of the Commission’s Form S-3 and Item 601(b)(5) of Regulation S-K Promulgated Under the Securities Act

from SC 13D/A ~1 page March 18, 2010 1. We Received an Email From Mike McGuinness on March 2, 2010 in Conjunction With Your Recent Financing. See Copy Below. Although Not Stated, the Email Implies a Revised Conversion Price for Our Put Rights of $0.07 Per Share and a Revised Strike Price for Our Warrant of $0.07 Per Share